Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase III trial studies combination chemotherapy and atezolizumab to see how well it
works compared with combination chemotherapy alone in treating patients with stage III colon
cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination
chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving combination chemotherapy with
atezolizumab may work better than combination chemotherapy alone in treating patients with
colon cancer.
-
Click here for details...
This phase III trial studies how well vitamin D3 given with standard chemotherapy and
bevacizumab works in treating patients with colorectal cancer that has spread to other parts
of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and
teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and
irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy
with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vitamin
D3 with chemotherapy and bevacizumab may work better in shrinking or stabilizing colorectal
cancer. It is not yet known whether giving high-dose vitamin D3 in addition to chemotherapy
and bevacizumab would extend patients' time without disease compared to the usual approach
(chemotherapy and bevacizumab).
-
Click here for details...
This phase II/III trial studies the best dose of duloxetine and how well it works in
preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with
oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount
of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in
patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent
peripheral neuropathy.
-
Click here for details...
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in
addition to standard of care chemotherapy and radiation therapy in patients with esophageal
and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with
antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's immune
system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and
radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be
removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and
radiation therapy might be more effective in patients with esophageal and gastroesophageal
junction adenocarcinoma who are undergoing surgery.
-
Click here for details...
This phase III trial compares the addition of nivolumab to chemotherapy (carboplatin and
paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that
has spread to other places in the body (metastatic). Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving nivolumab together with carboplatin and paclitaxel may help doctors find out if the
treatment is better or the same as the usual approach.
-
Click here for details...
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and
capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with
radiation therapy may kill more tumor cells. This study may help doctors find out if
lower-dose chemoradiation is as effective and has fewer side effects than standard-dose
chemoradiation, which is the usual approach for treatment of this cancer type.
-
Click here for details...
This phase III trial studies how well the addition of radiotherapy to the usual treatment
(chemotherapy) works compared to the usual treatment alone in treating patients with
esophageal and gastric cancer that has spread to a limited number of other places in the body
(oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to
kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin,
5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the
usual chemotherapy alone in treating patients with esophageal and gastric cancer.
-
Click here for details...
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy
(paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver.
Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. This study may help the study doctors
find out how well pevonedistat shrinks bile duct cancer of the liver when given alone and
when in combination with paclitaxel and carboplatin.
-
Click here for details...
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine
and cisplatin (chemotherapy) versus chemotherapy alone in treating patients with liver cancer
that cannot be removed by surgery (unresectable) or has spread to other places in the body
(advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It
works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor.
This may slow the growth and spread of tumor. Chemotherapy drugs, such as gemcitabine and
cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab
and atezolizumab with chemotherapy may kill more tumor cells in patients liver cancer than
chemotherapy alone.
-
Click here for details...
This randomized phase III trial studies how well combination chemotherapy, bevacizumab,
and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA)
mismatch repair colorectal cancer that has spread to other places in the body (metastatic).
Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as bevacizumab and atezolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients
with colorectal cancer.
-
Click here for details...
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA)
testing in the blood works in predicting treatment for patients with stage IIA colon cancer
after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood.
Finding ctDNA in the blood means that there is very likely some small amounts of cancer that
remain after surgery. However, this cancer, if detected, cannot be found on other tests
usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify
patients with colon cancer after surgery who do benefit, and those who do not benefit, from
receiving chemotherapy.
-
Click here for details...
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients
based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon
cancer.
-
Click here for details...
The investigators hypothesize that the combination of eflornithine and sulindac will be
effective in reducing a three-year event rate of adenomas and second primary colorectal
cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
-
Click here for details...
This phase II trial tests whether encorafenib and cetuximab with and without nivolumab works
to shrink tumors in patients with colorectal cancer that has spread to other places in the
body (metastatic) or that cannot be removed by surgery (unresectable). Encorafenib may stop
the growth of cancer cells by blocking some of the enzymes needed for proliferation.
Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein
called EGFR, which is found on some types of cancer cells. This may help keep cancer cells
from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread.. Giving encorafenib and cetuximab with nivolumab may be more effective at
stopping the growth of new cancer cells in patients with metastatic or unresectable
colorectal cancer than encorafenib and cetuximab alone.
-
Click here for details...
This study will examine the association between low muscle mass (myopenia) at diagnosis and
chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
|
